Coronavirus Notebook: Heterologous Vaccine Study Shows Positive Results, UK Offers Earlier Second Dose To Vulnerable People
A Regime Of Two Different Vaccines Could Lead To More Flexible Vaccination Campaigns
Executive Summary
The European Medicines Agency has extended the time that Comirnaty can spend in a fridge after defrosting and could this week issue advice to member states on sotrovimab for use in COVID-19 patients. Norway’s BerGenBio has published top-line data from a Phase II trial of of bemcentinib, and IcanoMAB has outlined the potential of its anti-IL-1R7 antibody.
You may also be interested in...
Coronavirus Notebook: UK Seven-Vaccine Booster Trial Begins, Australia Plans mRNA Production Capacity
The company manufacturing Russia's Sputnik V vaccine in Brazil has produced the first batch, but has withdrawn a request to run clinical trials there. France is preparing to immunize the over-18s, and Australia has begun evaluating Vir/GSK’s sotrovimab for use in COVID-19 patients.
EMA Reviews GSK/Vir’s COVID-19 Antibody To Support Early Use By Member States
After preliminary discussions with its pandemic task force, the European Medicines Agency has begun reviewing GSK/Vir Biotechnology’s promising COVID-19 treatment to help EU national competent authorities make evidence-based decisions on its possible early use.
Coronavirus Notebook: UK ‘Com-Cov’ Trial To Test Alternating Vaccines, EMA Pilots Assessment Sharing Scheme
The director of the World Health Organization and the NGO, Médecins Sans Frontières, have both called for monopolies on COVID-19 products to be waived during the pandemic. And confounding critics, new analysis in The Lancet shows the Oxford/AZ vaccine works best with a 12-week dosing interval.